Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript
Cytokinetics (CYTK) reported Q2 2026 revenue of $28.6M, down from $66.8M in 2025 due to fewer Bayer milestone payments, with MYQORZO net product revenue of $25.3M. Cash and investments were $1.7B after a May offering. Operating expense guidance was raised to $860M-$890M; net loss was $198.8M. MYQORZO new-to-brand share exceeded 40% in June.
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2026 operating costs, revenue trajectory, and the probability-weighted path to an expanded non-obstructive HCM label based on the disclosed regulatory calendar and launch adoption metrics.
Market read
This is a decision-oriented earnings call transcript with concrete launch KPIs, updated cost guidance, and specific regulatory dates that can reprice near-term risk and timelines.
What to watch
Administrative and benefits investigation cancellations (mid-single-digit prescriptions) and higher SG&A from launch costs may pressure near-term profitability even if prescriptions keep rising.
Background
The company is transitioning from research-focused operations to a global commercial enterprise following the MYQORZO launch.
Ticker impact
Cytokinetics reported Q2 2026 results and updated operating expense guidance, plus a Q4 2026 supplemental NDA and Nov. 14, 2026 PDUFA date.
Near-term bias positive on launch metrics and forward regulatory timeline, with volatility risk around safety (LVEF <50%) and administrative prescription cancellations.
The article discloses multiple decision-relevant datapoints: revenue decline drivers, dispensed patient growth, share capture, updated opex guidance, and specific regulatory milestones (sNDA timing and PDUFA date). It also flags concrete risks (10% LVEF <50%, serious heart failure events, mid-single-digit prescription cancellations).
Market effects
Reinforces commercial execution momentum for cardiac myosin inhibitor category, potentially affecting sentiment toward oHCM/nHCM development programs.
Germany launch and UK regulatory approval support incremental European adoption narrative.
Enrollment progress across North America, Europe, and China for COMET-HF may influence broader cardiology trial risk perception.
Counterpoint
Despite strong dispensed patient growth and share capture, the revenue base is still heavily milestone-dependent and safety signals (LVEF <50%) could constrain long-term uptake.
Key entities
- companyCytokinetics, Incorporated
Reported Q2 2026 financials, updated operating expense guidance, and provided regulatory and commercial launch milestones for MYQORZO and aficamten.
- productMYQORZO
Commercial launch in the U.S. and initial launch in Germany, with adoption metrics including new-to-brand share and dispensed patients.
- drug_programaficamten
Potential expansion into non-obstructive hypertrophic cardiomyopathy via supplemental NDA planned for Q4 2026; ACACIA-HCM safety and efficacy highlights discussed.
- clinical_trialACACIA-HCM
Phase 3 trial in non-obstructive hypertrophic cardiomyopathy with primary endpoint improvements and LVEF safety signal.
- clinical_trialCOMET-HF
Heart failure program with enrollment progress reported across regions.
